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Summary
Adenosine deaminase (ADA) deficiency causes lympho-
penia and immunodeficiency due to toxic effects of its
substrates. Most patients are infants with severe com-
bined immunodeficiency disease (SCID), but others are
diagnosed later in childhood (delayed onset) or as adults
(late onset); healthy individuals with “partial” ADA de-
ficiency have been identified. More than 50 ADA mu-
tations are known; most patients are heteroallelic, and
most alleles are rare. To analyze the relationship of ge-
notype to phenotype, we quantitated the expression of
29 amino acid sequence–altering alleles in the ADA-de-
leted Escherichia coli strain SØ3834. Expressed ADA
activity of wild-type and mutant alleles ranged over five
orders of magnitude. The 26 disease-associated alleles
expressed 0.001%–0.6% of wild-type activity, versus
5%–28% for 3 alleles from “partials.” We related these
data to the clinical phenotypes and erythrocyte deoxy-
adenosine nucleotide (dAXP) levels of 52 patients (49
immunodeficient and 3 with partial deficiency) who had
43 genotypes derived from 42 different mutations, in-
cluding 28 of the expressed alleles. We reduced this com-
plexity to 13 “genotype categories,” ranked according
to the potential of their constituent alleles to provide
ADA activity. Of 31 SCID patients, 28 fell into 3 ge-
notype categories that could express X0.05% of wild-
type ADA activity. Only 2 of 21 patients with delayed,
late-onset, or partial phenotypes had one of these “se-
vere” genotypes. Among 37 patients for whom pretreat-
ment metabolic data were available, we found a strong
inverse correlation between red-cell dAXP level and total
ADA activity expressed by each patient’s alleles in
SØ3834. Our system provides a quantitative framework
and ranking system for relating genotype to phenotype.
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Introduction
Deficiency of adenosine deaminase (ADA; MIM
102700), a 41-kD zinc enzyme encoded in a 12-exon/
32-kb gene on chromosome 20q, causes 10%–20% of
all cases of severe combined immunodeficiency disease
(SCID) (Giblett et al. 1972; Wiginton et al. 1984, 1986;
Wilson et al. 1991; Hershfield and Mitchell 1995). Pro-
found lymphopenia in this disorder has been attributed
to toxic levels of ADA substrates, particularly deoxy-
adenosine (dAdo), generated from nucleic acid break-
down associated with cell turnover in marrow, thymus,
and lymph nodes. Erythrocytes of deficient patients
show two striking effects of dAdo, dATP pool expansion
and inactivation of S-adenosylhomocysteine (AdoHcy)
hydrolase. These findings and in vitro studies have im-
plicated two pathogenic mechanisms—namely, inhibi-
tion by dATP of DNA replication and repair, inducing
apoptosis, and inhibition by AdoHcy of S-adenosyl-
methionine–dependent methylation (reviewed in Hersh-
field and Mitchell 1995). These or other effects of ADA
substrates also may cause hepatic injury in ADA knock-
out mice and in some human patients (Migchielsen et
al. 1995; Wakamiya et al. 1995; Bollinger et al. 1996).
Most ADA-deficient patients have SCID, which is usu-
ally diagnosed in infancy and is often fatal, but 15%–
20% are diagnosed later in childhood or as adults with
insidiously evolving immunodeficiency (Giblett et al.
1972; Hirschhorn 1979; Geffner et al. 1986; Levy et al.
1988; Santisteban et al. 1993; Shovlin et al. 1994;Hersh-
field and Mitchell 1995; Ozsahin et al. 1997). Healthy
individuals with “partial” ADA deficiency have also
been identified (Jenkins et al. 1976; Daddona et al. 1985;
Hirschhorn and Ellenbogen 1986; Hirschhorn et al.
1990; Santisteban et al. 1995b; Ozsahin et al. 1997). To
date, 150 ADA mutations, including 130 amino acid
substitutions, have been found in patients. Relating ge-
notype to phenotype has been difficult because ADA
deficiency is rare (∼1/106 births) and most new muta-
tions have been reported in single patients who often
are heteroallelic. Although unusual, mosaicism can oc-
cur, further complicating analysis (Hirschhorn et al.
1994, 1996).
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Assessment of residual ADA activity and the effects
of mutations on ADA expression has also been prob-
lematic. Obtaining lymphocytes from SCID patients is
rarely possible, and estimation of “percent of normal”
ADA activity from these cells or cell lines is imprecise.
Erythrocyte ADA activity, usually the only direct mea-
sure of residual activity available, is very low in all phe-
notypes (Hershfield and Mitchell 1995; Hirschhorn
1995). This may reflect low ADA expression and lack
of protein turnover in red cells, favoring loss of unstable
mutant enzymes. In studies defining ADA genotype, pu-
tative missense mutations have been distinguished from
polymorphisms, by transfection of cell lines with cDNA
or by translation of cDNA-derived transcripts in a re-
ticulocyte lysate. However, with either approach, en-
dogenous ADA activity has precluded quantitation of
mutant activity.
If information relevant to phenotype is to be derived
from genotype, it is essential to establish a uniform,
quantitative, and sensitive method for assessing effects
of mutations. This might be done by transfection of a
cell line derived from one of a few SCID patients known
to be homozygous for an ADA-gene deletion. However,
since ADA is active as an unmodified monomer and is
homologous to the Escherichia coli enzyme, we used a
more convenient expression system based on the ADA-
deleted E. coli strain SØ3834 (Chang et al. 1991; Ib-
rahim et al. 1995). We report an excellent correlation
between the expressed ADA activity of a panel of 29
mutant alleles and the clinical and metabolic phenotypes
of a diverse group of 52 patients who possessed 43 gen-
otypes derived from 42 different mutant alleles, includ-
ing 28 from the expression panel.
Patients, Material, and Methods
Criteria for Patient Selection and Phenotype
Classification
Reference Patients.—Over the past 15 years, we have
diagnosed or have been involved in monitoring the treat-
ment of ∼100 ADA-deficient patients. For this study,
patients were included if both genotype (both mutant
ADA alleles) and a fully developed clinical phenotype
(as defined in next section) were known, either from
clinical case reports, reports of new mutations that in-
cluded information about phenotype, or from our own
unpublished analysis of genotype. Affected sibs diag-
nosed prenatally or at birth were excluded, but for two
families both sibs were included, since they were diag-
nosed simultaneously and had distinctive phenotypes
(Shovlin et al. 1993; Umetsu et al. 1994). We also in-
cluded two healthy adults who were found to have par-
tial ADA deficiency and who are the father and an uncle
of unrelated SCID patients (Santisteban et al. 1995b;
Ozsahin et al. 1997).
Phenotype.—The level of dATP or total dAdo nucle-
otides (dAXP; 190% dATP) in erythrocytes, if measured
before transfusion, enzyme replacement, or marrow
transplant, is a sensitive index of metabolic severity as-
sociated with ADA deficiency (Hershfield and Mitchell
1995). Various parameters of cellular and humoral im-
mune function may be examined prior to these treat-
ments, but methods used and degree of documentation
have not been consistent. The terms “SCID,” “delayed
onset,” “late (adult) onset,” and “partial” deficiency
have been used to distinguish levels of overall clinical
severity and immune dysfunction (Hershfield andMitch-
ell 1995; Hirschhorn 1995). Since onset is often difficult
to pinpoint, we prefer to use age at diagnosis, which is
definite, as a reference. The delay between onset of symp-
toms and diagnosis has been estimated to average 2 mo
for patients with SCID (Stephan et al. 1993) and has
been 110 years for some patients diagnosed as adults
(Shovlin et al. 1993; Ozsahin et al. 1997). Thus, our
definitions are as follows: (1) SCID—profound lympho-
penia with absent cellular and humoral immune func-
tion, leading to recurrent opportunistic infections and
failure to thrive in infancy, with diagnosis in the 1st year
of life; (2) delayed onset—clinical deterioration due to
combined immunodeficiency, leading to diagnosis at 1
year to several years of age; (3) late onset—major im-
munologic and clinical deterioration, leading to diag-
nosis, occurs beyond the 1st decade; (4) partial—healthy
ADA-deficient individuals with normal immune func-
tion. Late-onset patients may be underdiagnosed, and
all “partials” have been ascertained by screening.
Bacterial Strains and Plasmids
E. coli SØ3834 and plasmid pZC11–containing TAC-
promoted wild-type human ADA cDNA (Chang et al.
1991) were kindly provided by Dr. Rod Kellems, Uni-
versity of Texas–Houston Medical School. E. coli
SØ3834 is a multiple auxotroph (rpsL, Dadd-uid-man,
metB, guaA, uraA::Tn10) with a deletion of add (bac-
terial ADA gene). When grown in minimal medium,
SØ3834 requires guanosine, owing to the guaA (guany-
late synthetase gene) mutation (Jochimsen et al. 1975;
Hove-Jensen and Nygaard 1989). After transformation
with a functional human ADA cDNA, this guanosine
requirement can be met by 2,6-diaminopurine (DAP)
(Chang et al. 1991). We confirmed this and found that
several mutant ADA cDNAs also conferred the ability
to grow on DAP, indicating that low levels of mutant-
ADA activity could supply sufficient guanine nucleo-
tides from DAP to support colony growth (data not
shown).
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Cloning and cDNA Manipulations
We constructed a panel of pZ/ADA cDNA transfor-
mants of SØ3834, consisting of wild-type and 29mutant
alleles (28 missense and 1 single-codon deletion), all of
which have been identified in ADA-deficient patients and
have been reported elsewhere (table 1). These mutations
alter 24 amino acids between positions 15 and 337 (of
363) of human ADA. Mutant ADA cDNAs were sub-
cloned into the pZC11 NcoI site from which wild-type
cDNA had been excised (pZ). In most cases, a 720-bp
BamHI/BglII or a 663-bp PstI fragment of wild-type
cDNA was replaced with a fragment containing the mu-
tation of interest. Mutations V129M, R149Q, A215T,
E217K, and R253P were introduced by combinatorial
PCR mutagenesis, essentially as described elsewhere for
the A215T and P126Q mutations (Ozsahin et al. 1997).
Final pZ cDNA inserts were sequenced in order to de-
termine that only the desired mutation was present.
cDNA Expression
In preliminary studies, we evaluated factors that could
influence expression and quantitation of low mutant-
ADA activity in pZ-transformed SØ3834. In complete
medium (to avoid selection for more-activemutants) and
without induction, levels of plasmids bearing wild-type
and several mutant cDNAs were relatively uniform in
late log phase, as were the different levels of ADA ac-
tivity that each expressed; isopropylthiogalactoside in-
duction had little effect on ADA expression. There was
no effect on assayed activity when purified ADA was
diluted extensively in a concentrated SØ3834 lysate, in-
dicating the functional absence of inhibitors or reactions
competing for substrate or product.
On the basis of these results, we developed the fol-
lowing protocol for determining ADA expression. pZ-
ADA transformants of SØ3834 were grown at 37C on
Luria-Bertani (LB) plates containing carbenicillin and
tetracycline (200 and 12.5 mg/ml, respectively). Several
colonies of each transformant were transferred to 10 ml
LB/carbenicillin/tetracycline medium and were grown at
37C to 0.8–1.2 A600. Aliquots of each culture (and pZ
vector–only controls) were tested for pZ retention. Cells
harvested from 3-ml aliquots of 3–4 cultures with equiv-
alent plasmid levels were sonicated in 100 ml of lysis
buffer (10 mM Tris-HCl, pH 7.5; 75 mM KCl; 10 mM
MgC12; 1 mM DTT; and 1 mM AEBSF protease inhib-
itor [Calbiochem]). After centrifugation (15,000 g, 15
min, 4C), ADA activity in supernatants (diluted as nec-
essary to achieve linearity in lysis buffer containing 1
mg BSA/ml) was determined by radiochemical assay (Ar-
redondo-Vega et al. 1990). Aliquots of supernatant con-
taining 20 mg of lysate protein also were analyzed by
10% SDS-mercaptoethanol PAGE and by western blot-
ting performed by standard techniques. For the latter,
we used goat anti-human ADA antiserum (Wiginton and
Hutton 1982) kindly supplied by Dr. Dan Wiginton,
University of Cincinnati; a rabbit anti-goat IgG-alkaline
phosphatase conjugate was the secondary antibody. A
lower limit of 0.4 ng of purified human ADA could be
detected when added to an untransformed SØ3834 lys-
ate prior to immunoblotting (data not shown).
Results
The 52 subjects who met criteria for inclusion include
49 with immune deficiency, who were from a few weeks
to 39 years of age at diagnosis, and 3 healthy subjects
with partial deficiency (table 2). For the 31 SCID pa-
tients, the average age at diagnosis was 4.4 mo. This is
similar to the ages reported in two large retrospective
studies of 1200 patients with SCID due to all causes
(15% of these were ADA deficient) (Stephan et al. 1993;
Buckley et al. 1997). Among our reference cases were
nearly all reported cases in the delayed and late-onset
categories.
Consistent with their clinical heterogeneity, the 52 ref-
erence patients possessed 43 ADA genotypes, composed
of 42 different mutant alleles, only 2 of which accounted
for 110% of the total (R211H, 13%; G216R, 11%)
(tables 1 and 2). Forty-four subjects (85%) had at least
1, and 31 (60%) had 2, of 28 alleles with mutations
that altered single amino acid residues. All 28 of these
alleles are included in the SØ3834 expression panel.
Mutant-Allele Expression in SØ3834
ADA activity expressed constitutively by the panel of
29 SØ3834 transformants ranged over about five orders
of magnitude, from a background of 3 nmol/h/mg lysate
protein for the pZ vector control to 262,600 nmol/h/mg
protein for wild-type human ADA (pZC11). The activ-
ities of the 29 mutants form a roughly monotonic con-
tinuum, from twice background to 74,000 nmol/h/mg
protein (fig. 1). Immunoblot bands for mutant proteins
ranged from undetectable to more intense than those for
wild type (fig. 2). The effects of mutations on ADA fold-
ing and stability will be the subject of a separate report,
but, in most cases, mutant proteins appeared to have
reduced stability. However, catalytic activity usually was
reduced to a greater extent than detectable protein. A
striking example is the active site mutation E217K,
which consistently appeared more stable than wild type,
on the basis of immunoblotting, but which had only
0.001% of wild-type ADA activity.
Relationship of Expressed ADA Activity to Clinical
Phenotype
Half of all alleles of the reference subjects and 14 of
their 28 amino acid substitutions occurred in single in-
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Table 1
ADA Mutations in Reference Patients
Mutation Site
No. of Alleles (No. of
Homozygous Patients)a Reference(s)
Expressed in SØ3834:
H15D Exon 2 1 Santisteban et al. 1995a
G74C Exon 4 1 Arredondo-Vega et al. 1997
G74V Exon 4 1 Bollinger et al. 1996
A83D Exon 4 1 Santisteban et al. 1995a
R101L Exon 4 1 Santisteban et al. 1993
R101Q Exon 4 2 Bonthron et al. 1985
R101W Exon 4 1 Akeson et al. 1988
P104L Exon 4 4 (2) Atasoy et al. 1993
L107P Exon 4 5 Hirschhorn et al. 1990
P126Q Exon 5 1 Ozsahin et al. 1997
V129M Exon 5 2 (1) Arredondo-Vega et al. 1997
G140E Exon 5 1 Arredondo-Vega et al. 1997
R142Q Exon 5 1 Santisteban et al. 1995b
R149W Exon 5 1 Arredondo-Vega et al. 1997
R149Q Exon 5 )b Hirschhorn et al. 1990
R156C Exon 5 3 (1) Hirschhorn 1992
R156H Exon 5 6 (1) Santisteban et al. 1993
V177M Exon 6 1 Santisteban et al. 1993
A179D Exon 6 1 Santisteban et al. 1995a
Q199P Exon 6 1 Arredondo-Vega et al. 1997
R211C Exon 7 2 Hirschhorn et al. 1990; Shovlin et al. 1994
R211H Exon 7 13 (4) Akeson et al. 1987, 1988
A215T Exon 7 1 Hirschhorn et al. 1990; Ozsahin et al. 1997
G216R Exon 7 11 (2) Hirschhorn et al. 1991; Santisteban et al.
1993; Ozsahin et al. 1997
E217K Exon 7 1 Hirschhorn et al. 1992
R253P Exon 8 2 (1) Hirschhorn et al. 1993
S291L Exon 10 2 Hirschhorn 1992; Santisteban et al. 1993
A329V Exon 11 6 (2) Akeson et al. 1988
E337del Exon 11 1 Arredondo-Vega et al. 1997
Deletion:
3.25 kb Prom, exon 1 2 (1) Markert et al. 1988
3.2 kb Prom, exon 1 2 Shovlin et al. 1994
130 kb Prom, exons 1–5 1 Hirschhorn et al. 1992
G462 Exon 5 2 (1) Arredondo-Vega et al. 1997
1050–1054 Exon 10 7 (1) Gossage et al. 1993; Santisteban et al. 1993
1114–1115 Exon 11 1 Santisteban et al. 1993
Splicing:
1GrA IVS 2, 5′ss 1 Arredondo-Vega et al. 1994
1GrA IVS 5, 5′ss Santisteban et al. 1995a
6TrA IVS 5, 5′ss 1 Santisteban et al. 1993
17 bp rearranged IVS 8, 3′ss 1 Arredondo-Vega et al. 1994
1GrA IVS 10, 5′ss 1 Santisteban et al. 1993
34GrA IVS 10, 3′ss 2 (1) Santisteban et al. 1993
Nonsense:
Q3X Exon 1 3 (1) Santisteban et al. 1995b
R142X Exon 5 2 (1) Santisteban et al. 1995b
NOTE.—Prom  promotor; ss  splice site.
a Among 100 alleles of 50 nonsibs.
b Not represented in reference population.
dividuals. To simplify assessment of the relationship to
phenotype, we grouped alleles, where possible, accord-
ing to their potential for providing functional ADA ac-
tivity. Deletion and nonsense alleles form group 0, under
the assumption that they provide no activity. The 29
amino acid substitutions in our panel were divided into
four contiguous groups of increasing ADA activity in
SØ3834 (fig. 1 and table 3). Group I, comprising 17
alleles with 0.001%–0.05% of wild-type activity, in-
cludes E217K and H15D, which alter substrate- and zinc
cofactor–binding residues (Wilson et al. 1991; Santis-
teban et al. 1995a), and the recurrent alleles R211H,
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Table 2
Reference-Population Characteristics
No. of Patients
Age at Diagnosis
(Range)
[years  SD]
Phenotype:
SCID 31 .36  .25 (.1–1)
Delayed onset 14 3.3  2.0 (1.2–8)
Late onset 4 30.6  10.5 (15–39)
Partial 3 )a
No. of Mutations
Mutation type:b
Missense 27
Deletion 7
Splicing 6
Nonsense 2
Total 42
NOTE.—The reference population comprised 52 patients with
defined clinical expression (see text for discussion of selection cri-
teria) and both alleles identified.
a Current age: 20–30 years.
b No. of different genotypes: 43 (19 homozygous).
G216R, A329V, L107P, and P104L. Group II has 6 al-
leles that expressed 0.06%–0.2% of wild-type activity,
including the recurrent allele R156H. Groups III
and IV each include 3 alleles, with 0.3%–0.6% and
4.8%–28.2% of wild-type ADA activity, respectively. Fi-
nally, splicing mutations (“spl”) are in a separate group,
and no assumption was made about their potential for
providing some normal ADA mRNA and functional en-
zyme. By use of these designations, each reference subject
fell into 1 of 13 “genotype categories” (table 4).
All 10 patients in genotype categories 0/0 and 0/I and
18 of 20 patients in category I/I had a SCID phenotype
(i.e., 28 of 31 SCID patients [90%] were in one of these
three categories). Homozygosity or “functional hemi-
zygosity” for the group I alleles R211H, G216R, L107P,
and P104L consistently was associated with an early
clinical presentation and diagnosis (Bory et al. 1990;
Hirschhorn et al. 1991; Atasoy et al. 1993; Weinberg et
al. 1993; F. X. Arredondo-Vega, I. Santisteban, M. S.
Hershfield, unpublished data). Thus, both probands in
two distantly related G216R-homozygous Amish fami-
lies had opportunistic infections that led to diagnosis
before 1 mo of age, and four unrelated R211H homo-
zygotes (three Hispanic and one Canadian) were diag-
nosed at 3, 4, 5, and 10 mo of age. Brazilian and U.S.
patients homozygous for P104L were diagnosed at 3 mo
of age, and two apparently unrelated French children,
who were heteroallelic for L107P and a 5-bp deletion
in exon 10, were diagnosed at 2 mo of age. The group
I allele with the highest activity, A329V, has occurred in
several SCID patients, including two unrelated homo-
zygotes, each diagnosed at 7 mo of age (Markert et al.
1987; Hershfield et al. 1993; Bollinger et al. 1996; F. X.
Arredondo-Vega, I. Santisteban, M. S. Hershfield, un-
published data).
Only 1 of 31 SCID patients carried an allele from
groups II–IV; he was heteroallelic for R211H and
A179D (category I/II) (Santisteban et al. 1995a). The
other five group II alleles were associated with a delayed-
onset phenotype in patients in genotype categories 0/II,
I/II, II/II, and II/spl. Among these, single patients diag-
nosed at 1.5–3 years of age were homozygous for A253P,
R156H, or V129M (category II/II); three others, diag-
nosed at 1.2–8 years of age, were heteroallelic for
R156H and either G216R (group I), a deletion, or a
splicing defect (Hirschhorn et al. 1993; Santisteban et
al. 1993; Arredondo-Vega et al. 1998; F. X. Arredondo-
Vega, I. Santisteban, M. S. Hershfield, unpublished
data). Single patients diagnosed at 4 and 6 years of age
carried V177M or Q199P (group II) and a deletion or
G216R, respectively (Santisteban et al. 1993; Arre-
dondo-Vega et al. 1998).
All three group III alleles have been associated with
delayed, late-onset, and partial phenotypes in heteroal-
lelic patients in genotype categories 0/III and I/III. Thus,
R211C (with a deletion) has been found in sisters who
developed immunodeficiency as adults and who were
diagnosed in their mid 30s (Shovlin et al. 1994), and
P126Q (with G216R) has been found in a Swiss patient
diagnosed at 39 years of age (Ozsahin et al. 1997).
R211C also has been found in a healthy partial whose
second allele was L107P from group I (Hirschhorn et
al. 1990). G74C has occurred in one patient, diagnosed
at 3 years of age, whose second allele was G216R (Ar-
redondo-Vega et al. 1998).
The three group IV alleles (R142Q, R149Q, and
A215T) have been found in healthy individuals who had
group I or nonsense mutations as their second alleles
(Hirschhorn et el. 1990; Santisteban et el. 1995b; Oz-
sahin et al. 1997). These alleles have not been found in
any patients with immunodeficiency. As we have pre-
viously noted, splicing mutations may be associatedwith
either severe or relatively mild phenotypes (Santisteban
et el. 1993; Arredondo-Vega et el. 1994). Thus, of six
reference patients with at least one splicing mutation,
two had SCID, three had a delayed phenotype, and one
had a late-onset phenotype (table 4).
Relationship of “Total Expressed ADA Activity” to
Metabolic Phenotype
Pretreatment dAXP or dATP levels were available for
37 of the reference subjects (23 SCID, 8 delayed onset,
3 late onset, and 3 partial) (table 5). This subset carried
26 of the 29 SØ3834 expression-panel alleles: 25 had
two panel alleles (12 were homozygous, and 13 were
compound heterozygous); 10 other patients were “func-
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Figure 2 Western blot of ADA expressed in lysates of SØ3834.
The panels are the results of three separate experiments. WT  wild-
type ADA, and SØ3834  pZ vector control (contains no ADA
cDNA).
Figure 1 Distribution of mutant-ADA activity expressed in SØ3834. The positive error bars indicate the SDs. The roman numerals and
dashed lines indicate the allele groups used in establishing the genotype categories (see text and tables 3 and 4).
tionally hemizygous,” with one panel allele and a second
allele contributing no or negligible ADA activity; and
two patients were homozygous for deletions.
On the basis of constitutive expression in SØ3834 (fig.
1), we calculated for each of these 37 subjects the total
ADA activity expressed by genotype (i.e., the sum of the
activity expressed by their alleles). The mean and ranges
of “total expressed ADA activity” and red-cell dAXP
levels for the four phenotypic groups are shown in table
5. There is probably a limit to the level to which dAXP
in cells can rise when ADA is deficient, in part because
the increase in dAXP is accompanied by a fall in ATP
(Siaw et al. 1980; Bagnara and Hershfield 1982). Nev-
ertheless, there was a good correlation ( ) betweenr  .9
total expressed ADA activity and RBC dAXP levels,
when data for individual patients were plotted (fig. 3).
The inverse nature of the relationship between ex-
pressed ADA activity and red-cell dAXP is apparent
from figure 3 and when the means for the four pheno-
types are compared (table 5). Of 23 SCID patients, 22
had dAXP 1350 nmol/ml RBC and 20 had total ex-
pressed ADA activity of !200 nmol/h/mg protein
(!0.04% of wild type). Conversely, all 14 patients with
delayed, late-onset, or partial phenotypes had red-cell
dAXP !300 nmol/ml, and 13 of 14 patients had total
expressed ADA activity 1190 nmol/h/mg protein. The
difference in means for total expressed ADA activity and
red-cell dAXP for the SCID and delayed-onset groups
was significant ( for each parameter; table 5).P ! .0001
The trends for the late-onset and partial groups were
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Table 3
ADA Mutants Grouped by Activity Expressed in SØ3834
Group Mutations
Expressed ADA
Activity (Range)
[nmol/h/mg protein]a
Percent of
Wild Type (Range)a
I H15D, G74V, A83D, R101L, R101Q, R101W,
P104L, L107P, G140E, R149W, R156C,
R211H, G216R, E217K, S291L, A329V,
E337del
30.4  35.8 (3.0–134.2) .012  .014 (.001–.051)
II V129M, R156H, V177M, A179D, Q199P, R253P 280  104 (164–456) .11  .04 (.06–.17)
III G74C, P126Q, R211C 1,093  487 (711–1,642) .42  .19 (.27–.63)
IV R142Q, R149Q, A215T 34,253  34,443 (12,492–73,963) 13.0  13.1 (4.8–28.2)
Wild type 262,593  21,590
a Mean  SD.
Table 4
Relationship of Genotype Category to Clinical Phenotype
GENOTYPE
CATEGORYa
NO. OF
PATIENTS
NO. OF PATIENTS,
BY PHENOTYPE
SCID
Delayed
Onset
Late
Onset Partial
Missense, deletion,
or nonsense:
0/0 5 5 ) ) )
0/I 5 5 ) ) )
I/I 20 18 2 ) )
0/II 1 ) 1 ) )
I/II 3 1 2 ) )
II/II 3 ) 3 ) )
0/III 3 ) 1 2 )
I/III 4 ) 2 1 1
0/IV 1 ) ) ) 1
I/IV 1 ) ) ) 1
Splicing:
I/spl 2 1 1 ) )
II/spl 1 ) 1 ) )
spl/spl 3 1 1 1 )
Total 52 31 14 4 3
a A 0 designates a deletion or nonsense allele; I, II, III, and IV
indicate an allele in the expressed-activity groups listed in table 3.
“spl” designates a splicing mutation. Among the five patients with a
0/0 genotype, three were homozygous for deletions, and two were
homozygous for nonsense mutations.
in the same direction, although the number of patients
in these groups was too few to adequately evaluate
significance.
Discussion
The clinical expression of immunodeficiency, on
which the diagnosis of ADA deficiency depends, can be
influenced strongly by environmental factors, such as
exposure to and treatment of pathogens, and also by
genes (other than that for ADA) that affect responses to
infection. Nevertheless, at the extremes, phenotype and
residual ADA activity clearly are related: blood mono-
nuclear cells from healthy subjects with partial deficiency
have 5%–70% of normal ADA activity, versus !1%–2%
in cells from patients with SCID. From reports of new
ADA mutations, albeit in small numbers of patients,
some splicing and missense alleles appear to be associ-
ated with delayed and late-onset phenotypes (Hirsch-
horn et al. 1990; Santisteban et al. 1993; Shovlin et al.
1994; Santisteban et al. 1995b; Ozsahin et al. 1997).
This suggests that allele combinations providing more
than some critical level of functional mutant enzyme (or
of normal ADA from splicing mutants) (Santisteban et
al. 1993; Arredondo-Vega et al. 1994) can confer a
milder phenotype than SCID. To more rigorously test
this hypothesis and to define this critical level of ADA
activity, we systematically compared the expression of
29 patient-derived amino acid substitutions distributed
throughout the ADA sequence.
ADA seemed well suited to expression analysis in E.
coli: it is cytoplasmic and active as an unmodified mono-
mer, and the human and E. coli enzymes are homologous
(Chang et al. 1991). One concern was that intrinsic ef-
fects of specific mutations might be obscured by non-
specific degradation. However, western blotting of
SØ3834 lysates (fig. 2) reproducibly revealed a broad
range of detectable mutant ADA proteins, consistent
with previous studies of patient-derived B lymphoblas-
toid cell lines, which used the same goat anti-human
ADA antiserum (Wiginton and Hutton 1982). In most
cases, less mutant than the wild-type ADA protein was
detected, but catalytic activity usually was reduced to a
greater degree. The mechanisms by which mutations af-
fect ADA activity—that is, by interfering with zinc or
substrate binding or with protein folding—are of interest
(and will be dealt with elsewhere). However, the question
posed in this study was not howmutations affect activity
but whether the level of expressed mutant activity cor-
relates well or poorly with aspects of phenotype.
For this study, the precision and sensitivity of the
SØ3834 system for scaling mutant expression greatly
exceed those for determining residual ADA activity in
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Figure 3 Relationship between allele-determined total expressed
ADA activity and erythrocyte dAXP levels. The total expressed
ADA–activity value (see text) for each of 37 subjects is plotted against
their pretreatment red-cell dAXP (or dATP) level. The phenotypes of
the subjects are indicated by the symbols defined in the figure. To use
a log scale, we assigned an expressed-ADA value of 1 nmol/h/mg
protein (not 0) to the two SCID patients homozygous for deletions.
ADA expression for a normal individual was assumed to be twice the
ADA activity expressed from wild-type ADA cDNA in SØ3834; the
normal red-cell dAXP level was assumed to be 1 nmol/ml of packed
RBC. The “power” least-squares algorithm of Cricket Graph III (Com-
puter Associates) was used for curve fitting (omitting the data points
for the two patients homozygous for deletions).
Table 5
Total Expressed ADA Activity and Erythrocyte dAXP Levels for Phenotype Groups
Phenotype
No. of
Patients
RBC dAXP (Range)
[nmol/ml]a
Expressed ADA
Activity (Range)
[nmol/hr/mg protein]a
SCID 23 766  344 (273–1,839)b 67  96 (1–314)b
Delayed onset 8 186  55 (100–263) 308  149 (72–522)
Late onset 3 122  104 (28–234) 855  122 (714–926)
Partial 3 15 12 (3–27) 29,144  39,247 (927–73,963)
Normal ) !2 525,184  43,180
a Mean  SD.
b , SCID vs. delayed onset.P ! .0001
cells that can be obtained from patients. Thus, ADA
activity expressed by wild-type ADA cDNA in SØ3834
was nmol/h/mg protein (mean ∼ 260,000 21,000
SD). With the same radiochemical assay, we found ADA
activity in normal red cells, blood mononuclear cells,
cultured T cells, and B lymphoblastoid cell lines to be
, , , and∼ 80 40 1,200 500 2,050 1,360
nmol/h/mg protein, respectively. Consis-7,450 3,300
tent with previous estimates that 5% of normal ADA
activity is sufficient to prevent immunodeficiency, three
alleles from healthy subjects with partial deficiency ex-
pressed 5%–28% of wild-type ADA activity in SØ3834.
However, the range expressed by the 26 disease-asso-
ciated alleles, 0.001%–0.6% of wild type, is 100-fold
greater than the 0.2%–1.1% of normal ADA activity
previously estimated for B cell lines derived from several
immunodeficient patients (genotype unknown) (Hirsch-
horn et al. 1979; Wiginton and Hutton 1982).
Two of the 29 mutants examined in SØ3834 also have
been expressed by mRNA translation in rabbit reticu-
locyte lysates (Santisteban et al. 1993; Hirschhorn et al.
1997; Ozsahin et al. 1997) and by transient transfection
of Cos cells (Hirschhorn et al. 1997). Relative ADA ac-
tivity (mutant vs. normal) was estimated from in situ
histochemical assay of electrophoresed extracts (per-
formed to resolve human from rabbit or monkey ADA).
In Cos cells, the partial A215T mutant was estimated
to have 8% of normal ADA activity, and the disease-
associated R156H mutant had 1.2% of normal ADA
activity (ADA protein was not evaluated) (Hirschhorn
et al. 1997). The expressed activities of these mutants
in SØ3834 were and of4.8% 1.3% 0.07% 0.01%
normal, respectively. The apparently higher levels in Cos
cells, particularly for R156H, may reflect characteristics
of the histochemical procedure. This coupled enzymatic
method, developed to detect ADA isozymes, produces a
colored precipitate at sites of ADA activity (Spencer et
al. 1968). Use for quantitation is problematic, since li-
nearity of color development is difficult to achieve and
to document; this problem is magnified when higher pro-
tein concentrations and longer incubations are needed
in order to detect mutant levels of activity, compared
with those needed to detect wild-type levels. Thus, the
relative activity of mutants with low but detectable ac-
tivity tends to be overestimated.
We related the SØ3834-activity data to clinical and
metabolic features of 52 patients, spanning the pheno-
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typic spectrum, who possessed 28 of the alleles in our
expression panel. These alleles were among 42 mutant
alleles that combined to give 43 genotypes. We reduced
this complexity by ranking genotypes, where possible,
according to the potential of their constituent alleles to
provide ADA activity. For this purpose, we divided the
expression-panel alleles into four groups with increasing
activity in SØ3834 (table 3). Group I, consisting of 17
alleles that expressed X0.05% of wild-type activity, in-
cludes several recurrent missense alleles that have been
considered to be “severe” because of their association
(when homozygous) with SCID. Groups III and IV in-
clude rare alleles that have been identified in patients
with late-onset and partial phenotypes.
By using these four allele groups and by grouping true
nulls (deletions and nonsense mutations) together and
splicing mutations separately, we assigned each patient
to 1 of 13 genotype categories. Constructing a table
relating these categories to the distribution of four clin-
ical phenotypes (table 4) revealed that 28 of 31 SCID
patients fell into three genotype categories that provided
X0.05% of normal ADA activity (i.e., the activity ex-
pressed by two copies of wild-type ADA cDNA in
SØ3834). Conversely, only 2 of 21 patients with delayed,
late-onset, or partial phenotypes had one of these “se-
vere” genotypes. The SØ3834 expression system should
provide a framework for evaluation of novel amino acid
substitutions. For example, we would expect that the
discovery of new patients with a delayed or late-onset
phenotype will result in new alleles that express activity
within the range for groups II and III.
In a subset of 37 patients for whom pretreatment met-
abolic data were available, we found a strong inverse
correlation between red-cell dAXP content and the sum
of the ADA activity expressed by their two alleles in
SØ3834. Nearly all SCID patients had red-cell dAXP
1350 nmol/ml RBC and total expressed ADA activity
!200 nmol/h/mg protein (0.04% of wild type). In con-
trast, nearly all patients with delayed, late-onset, or par-
tial phenotypes had red-cell dAXP !300 nmol/ml and
total expressed ADA activity 1190 nmol/h/mg protein.
Expressed ADA activity of cloned alleles is more likely
to be an index of steady-state residual ADA activity in
nucleated cells (capable of protein turnover) than in
erythrocytes, in which residual ADA activity usually is
undetectable. Our results support the hypothesis that
clinical phenotype–related red-cell dAXP levels reflect
differences in total residual capacity to catabolize cir-
culating dAdo (Cohen et al. 1978; Hershfield et al. 1987;
Santisteban et al. 1993; Hershfield and Mitchell 1995).
Erythrocyte dAXP levels in individual patients also may
reflect rates of dAdo production, transport into red
cells, and renal excretion, but differences in these factors
are unlikely to be related systematically to clinical
phenotype.
Our results indicate that clinical phenotype is affected
significantly by a remarkably low level of residual ADA
catalytic activity, that is, ∼0.05% of normal. Possession
of more than this activity may reduce metabolic toxicity
to a degree that permits sufficient survival of functional
T cells, in the 1st year of life or beyond, to protect from
the kinds of severe opportunistic infections that arouse
clinical suspicion of SCID and prompt testing for ADA
deficiency. Patients with delayed onset often experience
recurrent infections, and these infections may involve
pathogens that only occasionally affect normal children.
However, aggressive use of antibiotics can mask the un-
derlying problem of immunodeficiency and delay its
diagnosis.
Paradoxically, ADA-deficient patients with delayed
phenotype and probably most with late-onset phenotype
have persistent lymphopenia, which, if appreciated,
could identify them as being at risk of having combined
immunodeficiency early in life (if not at birth), before
clinical disease is manifested. Indeed, mandating lym-
phocyte counts for all infants, as a screen for a number
of primary immunodeficiency disorders, is of interest.
For patients identified in this manner as being ADA de-
ficient, predicting the course of the disorder and choos-
ing among several treatment options could pose prob-
lems. The ability to evaluate risk, and possibly the
response to enzyme-replacement therapy, on the basis of
genotype-determined expression of ADA activity, could
be useful in this situation.
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